June 13, 2025
´ºÓêÖ±²¥app
A research group from the Division of Pharmacotherapeutics, Faculty of Pharmacy, ´ºÓêÖ±²¥app, led by Kazuki Iida (first-year student, Doctoral Programs), Yuya Matsui (sixth-year student, Department of Pharmacy), and Professor Yoshimasa Saito, analyzed large-scale real-world data from 7,773 patients with biliary tract cancer, including genomic information, survival times, and treatment details. They revealed that mutations in the KRAS gene, a type of driver gene, are strongly associated with poor patient prognosis and resistance to current drug therapies, including immune checkpoint inhibitors. The findings of this study bring a new perspective to personalized treatment strategies for biliary tract cancer and were published in the online edition of "ESMO Open," a journal of the European Society for Medical Oncology (ESMO), on June 11, 2025.
Please see below for the full press release.